- Home
- IVVD vs SVII Comparison
IVVD vs SVII Comparison
Compare IVVD & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- SVII
- Stock Information
- Founded
- IVVD 2020
- SVII 2021
- Country
- IVVD United States
- SVII United States
- Employees
- IVVD N/A
- SVII N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- SVII Blank Checks
- Sector
- IVVD Health Care
- SVII Finance
- Exchange
- IVVD Nasdaq
- SVII Nasdaq
- Market Cap
- IVVD 123.8M
- SVII 113.1M
- IPO Year
- IVVD 2021
- SVII 2022
- Fundamental
- Price
- IVVD $0.59
- SVII $11.67
- Analyst Decision
- IVVD Strong Buy
- SVII
- Analyst Count
- IVVD 3
- SVII 0
- Target Price
- IVVD $7.52
- SVII N/A
- AVG Volume (30 Days)
- IVVD 1.9M
- SVII 7.7K
- Earning Date
- IVVD 05-15-2025
- SVII 01-01-0001
- Dividend Yield
- IVVD N/A
- SVII N/A
- EPS Growth
- IVVD N/A
- SVII N/A
- EPS
- IVVD N/A
- SVII 0.33
- Revenue
- IVVD $25,384,000.00
- SVII N/A
- Revenue This Year
- IVVD $606.63
- SVII N/A
- Revenue Next Year
- IVVD $83.30
- SVII N/A
- P/E Ratio
- IVVD N/A
- SVII $35.81
- Revenue Growth
- IVVD N/A
- SVII N/A
- 52 Week Low
- IVVD $0.36
- SVII $11.03
- 52 Week High
- IVVD $2.74
- SVII $11.70
- Technical
- Relative Strength Index (RSI)
- IVVD 46.76
- SVII 76.18
- Support Level
- IVVD $0.49
- SVII $11.63
- Resistance Level
- IVVD $0.80
- SVII $11.69
- Average True Range (ATR)
- IVVD 0.08
- SVII 0.02
- MACD
- IVVD 0.01
- SVII 0.01
- Stochastic Oscillator
- IVVD 32.79
- SVII 90.48
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.